TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ReShape Lifesciences ( (RSLS) ) has provided an announcement.
On July 24, 2025, ReShape Lifesciences Inc. held a special meeting where stockholders voted on several proposals, including the issuance of shares for a merger with Vyome Therapeutics, and a reverse stock split. The meeting was adjourned to further discuss the sale of the company’s assets to Ninjour Health International and amendments to the company’s incorporation certificate, with the meeting set to resume on August 7, 2025.
Spark’s Take on RSLS Stock
According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.
ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.
To see Spark’s full report on RSLS stock, click here.
More about ReShape Lifesciences
ReShape Lifesciences Inc. operates in the medical device industry, focusing on products and services related to weight loss and metabolic health.
Average Trading Volume: 2,703,221
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.51M
See more insights into RSLS stock on TipRanks’ Stock Analysis page.